New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
08:48 EDTKPTIKaryopharm initiates study of Selinexor in older AML patients
Karyopharm Therapeutics announced the initiation of its Phase 2 study of Selinexor in patients 60 years of age or older with relapsed or refractory acute myeloid leukemia, or AML, who are ineligible for intensive chemotherapy and/or transplantation. This Selinexor in Older Patients with Relapsed/Refractory AML, or SOPRA, study is a randomized trial of Selinexor, the company's novel oral Selective Inhibitor of Nuclear Export compound, versus physician's choice, and will be conducted at approximately 40 sites worldwide including sites in the United States, Canada, Europe and Israel.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
10:00 EDTKPTIOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AcelRx (ACRX) initiated with a Buy at H.C. Wainwright... Adobe (ADBE) initiated with a Perform at Oppenheimer... Antero Midstream (AM) initiated with a Buy at Ladenburg... Arbutus Biopharma (ABUS) initiated with an Outperform at JMP Securities... CSI Compressco (CCLP) initiated with a Market Perform at Wells Fargo... Cepheid (CPHD) initiated with an Equal Weight at Barclays... Cincinnati Financial (CINF) initiated with a Buy at MKM Partners... Disney (DIS) initiated with an Outperform at CLSA... Genomic Health (GHDX) initiated with an Underweight at Barclays... Green Brick (GRBK) initiated with a Neutral at Citi... Heron Therapeutics (HRTX) initiated with a Buy at BofA/Merrill... Karyopharm (KPTI) initiated with an Overweight at JPMorgan... PayPal (PYPL) initiated with a Buy at Argus... Quidel (QDEL) initiated with an Overweight at Barclays... Recro Pharma (REPH) initiated with a Buy at H.C. Wainwright.
07:07 EDTKPTIKaryopharm initiated with an Overweight at JPMorgan
Subscribe for More Information
August 19, 2015
08:53 EDTKPTIConcerns over Karyopharm overdone, says Wedbush
After eight AML patients taking Karyopharm's Sellinexor developed Sepisis versus two in the control arm, Wedbush quotes a doctor as saying that differences in patients' characteristics between the two arms may have contributed to the high rate of Sepsis in those taking Sellinexor,. Wedbush believes that a study of the 60 mg version of the drug, due out in 4Q16, will show that it improves survival and has an acceptable safety profile. Wedbush increased its discount rate on AML to 45% from 30% to account for higher risk from a reduced dose and cut its price target on the name to $39 from $50, mostly due to the postponement of clinical trial results. However, the firm keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use